Oxford Corona Vaccine: Phase III Clinical Trials in USA
As the hunt for effective vaccine against SARS-CoV-2 is at its high, the Corona Vaccine being developed in collaboration between AstraZeneca and University of Oxford entered into Phase III Clinical Trials to ensure its safety and efficacy in large population in USA.
In spite the trails already began in UK, Brazil and South Africa, the Oxford Vaccine (AZD1222) now started its Double-Blind clinical Trials in USA on a population size of 30,000.
Having had the data out of the trial results the government in association with the firms wish to launch its to common public by end of this year at least by temporary approval.
From the people who were administered with a dose of this Vaccine, assumed to have promising immune response and more the T- cell response which is desired to combat the COVID-19.
Biotech company Oxford Biomedica announced that it had expanded an agreement with AstraZeneca to produce 10 times as much of the Oxford vaccine as previously agreed.
Looking forward for an effective vaccine to combat the Corona Virus in very near future.
